These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18945509)

  • 101. Sulphonylureas and cancer: a case-control study.
    Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
    Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 105. [Sulphonylurea derivatives and the cardiovascular system].
    Filipiak KJ
    Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
    Sadikot SM; Mogensen CE
    Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].
    Asvold BO; Jonsbu M; Grill V
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2560-4. PubMed ID: 11070997
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
    Zargar A; Basit A; Mahtab H
    J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
    [TBL] [Abstract][Full Text] [Related]  

  • 109. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

  • 110. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 111.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 112.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 6.